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Summary
Objectives: To assess the efficacy of a single, oral dose of etodolac (300 mg), a nonsteroidal antiinflammatory drug, on gait and pain in
patients with unilateral hip osteoarthritis (hOA).
Design: Sixteen patients (8 F, 8 M; mean age: 61±11.2 years) with painful hOA were included in a randomized, crossover, double-blind study
versus placebo. Space and time parameters were assessed using Bessou’s locometer and pain was evaluated using the visual analog scale
(VAS) at t0 (before taking the drug), t60 (min), t120, and t180 after taking a 300-mg tablet of etodolac.
Results: Walking speed was significantly faster only between t0 and t180 under etodolac versus placebo (P<0.02). Walking speed increased
between t0, t60, t120 and t180 with etodolac (P<0.003), but not with placebo. Stride length increased (P<0.0001) only on the hOA side, while
the time parameters of gait for etodolac- and placebo-treated patients did not differ. VAS values differed significantly at t0 (P<0.01) between
etodolac and placebo groups, but no significant difference was observed at t60, t120 and t180.
Conclusions: Bessou’s locometer was able to demonstrate the efficacy of 300 mg of etodolac on gait in hOA. Walking speed was faster
3 h after taking the drug, essentially due to a greater stride length. Pain reduction in the etodolac group contributed to gait improvement.
It was concluded that gait performances improved because of less hip pain and thus a greater range of motion after etodolac intake.
© 2000 OsteoArthritis Research Society International
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Osteoarthritis (OA) of lower limbs is often treated with a
nonsteroidal antiinflammatory drug (NSAID), with two
objectives: reduction of joint pain and improvement of gait.1
NSAIDs are widely prescribed to reduce joint pain and
stiffness in OA, although their use in this condition remains
controversial,2 because the inflammatory component of
OA is relatively mild.2 In trials, the effects of an NSAID on
pain in hip osteoarthritis (hOA) is usually evaluated by
subjective clinical assessment using the visual analog
scale (VAS).3,4 NSAID effects on disability and gait are
usually evaluated by patient satisfaction, Lequesne’s index
of severity for hOA,5 or the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC).6 These
indices, however, are subjective and require a well-trained
investigator.5 The measurement of spatiotemporal par-
ameters of gait using Bessou’s locometer provides a quan-
titative and objective analysis of the human gait.7,8 This
method was previously used to evaluate the effectiveness
of a 7-day NSAID treatment for knee OA,9 but without a
placebo group. We previously conducted an open pilot230study which showed faster walking speed due to the
improvement of spatial but not temporal parameters in hOA
patients treated with NSAID and/or an analgesic drug, and
to attenuation of pain.10 However, no definitive conclusions
could be drawn because of the lack of a control group. The
aims of the present study were to assess the efficacy of
etodolac in hOA on (i) gait as assessed by Bessou’s
locometer, and (ii) pain with the VAS.Materials and methodsReceived 29 June 1998; accepted 11 November 1999.
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Sixteen outpatients (8 F, 8 M), who consulted our depart-
ment because of painful unilateral hOA, were included in
this study. Entry criteria were: patients with idiopathic hOA,
radiographic evidence of unilateral hOA, meeting ACR
criteria,11 daily pain for more than 1 month requiring the use
of an NSAID, VAS ≥30 mm. Patients were excluded if they
had: symptomatic arteritis of the lower limbs; gait-modifying
neurologic, muscle or articular diseases of the lower limbs
(except hOA); known or suspected allergy to etodolac or
paracetamol; renal insuffiency (serum creatinine level
>2 mg/dl); active liver disease; or treatment with oral,
parenteral or intraarticular steroids within the previous
month. Pregnant women and women of childbearing age
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istics of patients at inclusion are presented in Table I.ETHICS
This study was approved by the local Ethics Committee
(CCPPRBHN), and all the patients gave their written
consent before being enrolled in the study.PROTOCOL
Patients were included in a randomized, crossover,
double-blind study versus placebo. The drug used was
etodolac, 300 mg given in a single dose, ingested with a
glass of water on an empty stomach after fasting overnight.
For this study, a single dose intake was chosen because of
the crossover method. The placebo was kindly provided by
Wyeth-France, Paris.
All patients underwent a physical examination on day-7
(7 days before the first gait recording), and then entered
into a 7-day NSAID-washout period. Patients were random-
ized into two groups. Gait analysis was performed 1 week
(day 0) and 2 weeks later (day 7). For group 1, spatio-
temporal gait parameters were recorded on day 0 before
taking the etodolac tablet (t0), then 60 min (t60), 120 min
(t120) and 180 min (t180) afterwards. After another 7-day
NSAID-washout period, spatiotemporal gait parameters
were again recorded, according to the same protocol, on
day 7 before and after taking the placebo. For group 2, the
placebo was given on day 0, and etodolac on day 7. At the
time of each gait recording, pain was assessed by VAS.
During the time (60 min) between two spatiotemporal
gait-parameter recordings, patients were free to walk in
the hospital grounds. For all patients, only paracetamol
(≤3 g/d) was allowed during the washout periods, and was
stopped at least 8 h before gait recording.GAIT ANALYSIS
Spatiotemporal gait parameters were assessed using
Bessou’s locometer.7 Briefly, two identical devices were
designed to record simultaneously the longitudinal dis-
placements of each foot during gait: each device is com-
posed of a movement amplitude reducer made of pulleys. A
linen thread is wound around the pulleys and tied to the
foot. Patients are instructed to move the right foot first to
cover a 7-m walkway, with their natural gait. During gait, the
displacements of the pulleys corresponding to the displace-
ment of each foot are transmitted to a potentiometer. The
electrical signals from the potentiometers are proportional
to the distances covered by feet, and are amplified and
recorded by a computer as a ‘locogram’ (Fig. 1). From such
a locogram, two types of measurements are obtained:
spatial parameters (stride and step lengths), time par-
ameters (cycle, support, double-limb support and swing
durations, and early- and late-swing phases which are the
two components of the foot swing). From spatial and time
parameters, other parameters are calculated: cadence,
walking speed, swing speed, early-swing and late-swing
phase speeds.Table I
Patient characteristics
Patient Age
(years)
Sex Weight
(kg)
Height
(cm)
VAS pain
intensity
(mm)
Daily pain
duration
(months)
Lequesne’s
index
1 40 M 64 175 35 20 5
2 58 M 96 171 58 48 12
3 72 F 58 152 53 7 11
4 68 M 73 172 35 6 4
5 40 F 61 168 31 24 8
6 64 M 94 171 30 24 12.5
7 73 F 60 161 53 12 12
8 61 M 83 166 44 5 9.5
9 51 F 57 170 30 36 8.5
10 62 M 75 171 51 6 12.5
11 69 F 77 163 61 6 9
12 65 F 70 157 84 7 18
13 47 M 74 180 32 60 7
14 67 F 64 155 80 13 14.5
15 62 M 68 173 52 16 6.5
16 77 F 80 155 65 16 11.5
m±SD* 61±11 8F/8M 72±12 166±8 49±17 19±16 10±3.6
*Mean±standard deviation.STATISTICAL ANALYSIS
The number of patients needed to measure an increase
in walking speed up to one standard deviation was 16, with
an alpha risk of 0.05 and a beta risk of 0.10, considering
the normal values of walking speed obtained in healthy
subjects.7
Collected data at the different times evaluated during the
study were pooled according to treatment, and etodolac
and placebo groups were compared. Friedman’s test was
applied to all the parameters from t0 (before taking the
drug) to t180 (180 min after taking the drug).
For parameter changes from baseline (t0) assessed at
t60, t120 and t180, the modified Mann-Whitney test (Hill
Armitage) was used for the crossover method.
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Curves obtained in patient no. 12 before (t0) and 3 hours
(t180) after taking 300 mg of etodolac are reported in Fig. 2
(a and b respectively).WALKING SPEED
We first verified that walking speed was not statistically
different between etodolac and placebo groups at t0
[mean±standard deviation (m±SD): 3.54±0.53 and
3.67±0.57 km/h, respectively]. Walking speed increased
significantly between t0 and t180 under etodolac, but not
placebo (P<0.0004). Walking speed change was signifi-
cantly higher only between t0 and t180 with etodolac than
placebo (P<0.03). Individual percentages of walking speed
improvement for 16 patients between t0 and t180 with
placebo and with etodolac are shown in Fig. 3a.CADENCE
Cadence expressed in cycles/min, did not differ
statistically between etodolac and placebo groups (m±SD,
respectively, at t0: 103.0±9.0 and 104.4±11.2; at t60:
105.0±9.6 and 105.8±10.6; at t120: 105.2±12.4 and
106.6±11.4; at t180: 106.2±10.0 and 105.6±12.4).OTHER SPATIOTEMPORAL GAIT PARAMETERS (TABLE II)
Because the walking speed change differed significantly
between etodolac and placebo groups only between t0 and
t180, changes of other spatiotemporal gait parameters
were only compared between t0 and t180.On the hOA side, stride and step lengths increased
significantly under etodolac but not placebo (P<0.0001 and
P<0.05, respectively). Stride- and step-length changes
were significantly greater between t0 and t180 for the
etodolac than the placebo group (P<0.03 and P<0.04,
respectively). No difference between treatment groups was
observed for time parameters. Swing and early-swing
speeds increased with etodolac but not placebo (P<0.04).
Swing and early-swing speed changes were significantly
greater between t0 and t180 for the etodolac group
(P<0.05). The late-swing speeds for the two treatment
groups were statistically comparable.
On the healthy side, spatiotemporal gait parameters and
parameter changes between etodolac and placebo groups
did not differ statistically between t0 and t180.Fig. 1. Locogram with on the y-axis the distance in meters, and on
the x-axis the time in seconds. Each curve represents the longitu-
dinal displacement of each foot: when a foot is in contact with the
floor, the curve is parallel to the x-axis; the curve rises when a foot
is swinging. The horizontal and vertical lines provide, respectively,
the spatial and temporal parameter values of one walking cycle, of
each foot. The spatial parameters are step and stride lengths. The
temporal parameters are: cycle duration; support duration, double-
limb support duration; swing duration; early- and late-passing
phase durations, which are the two phases of the swing phase.Fig. 2. Locogram obtained in patient no. 12 before (t0) and 3 hours
after taking etodolac (t180) [a and b respectively], showing the
improvement of the asymmetrical gait, and the improvement of
the curve slope due to the improved walking speed.PAIN
VAS scores decreased significantly between t0 and t180
for etodolac and placebo groups (P<0.0009 and P<0.03,
respectively). At t0, VAS scores were significantly higher for
Osteoarthritis and Cartilage Vol. 8 No. 3 233the etodolac group (m±SD: 54.8±19.3 mm) than the
placebo group (m±SD: 37.2±20.4 mm) (P<0.01); by t180,
the mean VAS scores for the two treatment groups had
become statistically comparable. Individual percentages of
VAS improvement for the 16 patients under the effect of
each agent are given in Fig. 3b.Fig. 3. Percentages of improvement or deterioration of walking speed (a) and VAS (b) for each patient between t0 and t180, respectively,
under placebo ( ) and with etodolac ( ).Discussion
In a previous study, we established the normal values of
gait parameters according to age and gender.8 Bessou’s
locometer is easy to use and provides reproducible
simultaneous recordings of the spatiotemporal parameters
of both feet during walking.7 In our study, four patients were
overweight, but because each patient was his own control
(crossover design), this did not consequence the results.
In this double-blind, crossover study, we showed that
walking speed increased under etodolac, but not placebo.
Thus, we confirmed the findings of our earlier pilot study
and conclude that gait improvement was closely associated
with the administration of a single, oral 300-mg dose of
etodolac. Three hours after taking a single tablet, gait was
improved. Kraml et al. calculated the time to reach the
maximum intra-articular etodolac concentration to be 3 h,12
which probably explains why we found no difference
between t0 and t60, and t0 and t120; differences were
statistically significant only between t0 and t180.Lequesne’s index for our patients ranged between 4
and 14.5, consistent with mild hOA and moderately
impaired gait-performance. It would be worthwile to deter-
mine whether gait also improves under NSAID use for
patients with higher Lequesne’s indexes (i.e., those with
preoperative hOA).
For healthy subjects, spatial parameter increases (stride
and step lengths), temporal parameter decreases (cycle,
support and swing durations) or cadence increases are
different ways by which walking speed may increase.13 In
our study, faster walking speed was not attributable to
either lower temporal parameters in the etodolac group or
increased cadence, but could be explained by significantly
increased stride and step lengths on the hOA side.
In hOA, articuler stiffening and pain lead to a restricted
range of flexion-extension.14 Step corresponds mainly to
the range of hip flexion and stride to the range of hip
flexion-extension. Therefore, we conclude that the improve-
ment of spatial gait parameters after etodolac intake, only
on the hOA side, was due to the improved flexion-extension
range of the affected hip. The early-swing phase speed
increase of the affected hip could be explained by greater
extension. Indeed, spatial gait parameter increases seem
to be due to the effect of etodolac on hOA stiffening.
In our study on the healthy side, even if the step length
increased between t0 and t180 in the placebo group (from
58±6 to 61±7), an apparently higher increase in step
234 O. Mejjad et al.: Etodolac improves gait in hip osteoarthritislength was also seen in the etodolac group between t0 and
t180 (from 56±1 to 61±8). However, there was no statisti-
cal difference in the step-length changes between etodolac
and placebo groups between t0 and t180. Therefore, in our
study, the healthy side step length of the healthy side was
not affected by the stiffness of the hOA side, probably
because Lequesne’s index for our patients ranged between
4 to 14.5, consistent with mild hOA.
According to the literature, NSAIDs reduce pain caused
by hOA.15 In our study, pain was significantly lower 3 h
after taking etodolac than the placebo (P<0.0009 vs
P<0.03), even though pain had been significantly higher
in the etodolac group compared with placebo at t0. Thus,
3 h after taking a single 300-mg dose of etodolac, the
diminution of hOA-attributable pain probably contributed to
gait improvement.
In conclusion, the results of this study showed that, 3 h
after taking a single, 300-mg dose of etodolac, gait of hOA
patients was improved. This efficacy was assessed by a
quantitative analysis of gait, using a reliable objective tool,
the Bessou’s locometer.Acknowledgments
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Spatiotemporal gait parameters of etodolac- and placebo-treated groups, on the hOA side and the healthy side
(hs)
Parameter t0 t180
hOA side hs hOA side hs
Stride length (cm) Etodolac 114±15 114±16 121±12 121±13
Placebo 118±12 118±13 119±12 119±12
Step length (cm) Etodolac 58.8±8 56±10 61± 7 61± 8
Placebo 59± 8 58± 6 58± 9 61± 7
Cycle duration (s) Etodolac 1.2±0.1 1.2±0.1 1.1±0.1 1.1±0.1
Placebo 1.2±0.1 1.2±0.1 1.2±0.2 1.2±0.1
Support duration (s) Etodolac 0.69±0.09 0.7±0.08 0.68±0.09 0.68±0.09
Placebo 0.7±0.08 0.7±0.09 0.7±0.1 0.71±0.1
Swing duration (s) Etodolac 0.48±0.07 0.47±0.07 0.46±0.05 0.45±0.05
Placebo 0.45±0.06 0.46±0.06 0.46±0.07 0.45±0.07
Double support duration (s) Etodolac 0.11±0.04 0.12±0.05 0.11±0.04 0.13±0.04
Placebo 0.12±0.05 0.13±0.04 0.12±0.04 0.15±0.04
Early-swing duration (s) Etodolac 0.24±0.05 0.24±0.03 0.23±0.04 0.23±0.03
Placebo 0.23±0.01 0.23±0.03 0.23±0.04 0.22±0.04
Late-swing duration (s) Etodolac 0.24±0.03 0.23±0.05 0.23±0.03 0.22±0.03
Placebo 0.23±0.03 0.23±0.04 0.23±0.04 0.23±0.04
Swing speed (cm/s) Etodolac 242±39 247±38 265±29 269±33
Placebo 264±32 259±32 265±34 270±33
Early-swing speed (cm/s) Etodolac 238±40 249±36 267±35 268±37
Placebo 262±29 258±29 268±27 269±29
Late-swing speed (cm/s) Etodolac 247±42 247±44 266±32 271±33
Placebo 264±41 261±36 262±52 273±40
Values are means±standard deviations.References
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